Guided Therapeutics (GTHP) Net Margin (2016 - 2025)
Historic Net Margin for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 1308.33%.
- Guided Therapeutics' Net Margin changed N/A to 1308.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 1575.28%, marking a year-over-year increase of 46352500.0%. This contributed to the annual value of 37014.29% for FY2024, which is 331785700.0% down from last year.
- As of Q3 2025, Guided Therapeutics' Net Margin stood at 1308.33%.
- In the past 5 years, Guided Therapeutics' Net Margin registered a high of 268.42% during Q3 2021, and its lowest value of 70000.0% during Q4 2024.
- Over the past 5 years, Guided Therapeutics' median Net Margin value was 4404.55% (recorded in 2023), while the average stood at 17257.36%.
- Per our database at Business Quant, Guided Therapeutics' Net Margin soared by 378100000bps in 2022 and then plummeted by -685343800bps in 2024.
- Quarter analysis of 5 years shows Guided Therapeutics' Net Margin stood at 848.33% in 2021, then crashed by -4041bps to 35133.33% in 2022, then surged by 96bps to 1465.62% in 2023, then crashed by -4676bps to 70000.0% in 2024, then soared by 98bps to 1308.33% in 2025.
- Its Net Margin was 1308.33% in Q3 2025, compared to 731.62% in Q2 2025 and 70000.0% in Q4 2024.